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Genes in the Wnt (wingless)/𝗽𝗽-catenin signaling pathway have been implicated in schizophrenia pathogenesis. No study has
examined this pathway in the broader context of psychosis symptom severity. We investigated the association between symptom
severity scores and expression of 25 Wnt pathway genes in blood from 19 psychotic patients. Signi�cant correlations between
negative symptom scores and deshivelled 2 (DVL2) (𝑟𝑟adj =− 0.70; 𝑃𝑃=0.0008) and glycogen synthase kinase 3 beta (GSK3B)
(𝑟𝑟adj = 0.48; 𝑃𝑃=0.039) were observed. No gene expression levels were associated with positive symptoms. Our �ndings suggest
that the Wnt signaling pathway may harbor biomarkers for severity of negative but not positive symptoms.
1. Introduction
e Wnt (wingless)/𝗽𝗽-catenin signaling pathway is involved
in a multitude of neuronal processes including regulation of
synaptogenesis, synapse speci�city, axon guidance, dendrite
development, and overall brain development [1]. Numerous
genes involved in the Wnt/𝗽𝗽-catenin signaling pathway have
beenimplicatedinthepathogenesisofseveralneurodevelop-
mental disorders including schizophrenia, bipolar disorder,
and autism spectrum disorders [2]. While psychosis is a
key feature of schizophrenia and present in many cases of
bipolar disorder, to date the relationship between the Wnt/𝗽𝗽-
cateninsignalingpathwayandsymptomseverityinpsychosis
has not been investigated. us, we sought to correlate
blood-based gene expression of the Wnt/𝗽𝗽-catenin signaling
pathwaywithnegativeandpositivesymptomseverityindices
of patients with a history of psychosis (i.e., schizophrenia or
bipolar disorder). We were guided by previous research that
has examined the relationship between psychosis symptom
severity and other gene expression pathways in peripheral
blood [3, 4]a n dh a sd e m o n s t r a t e dt h eu t i l i t yo fb l o o da sa
source of biomarkers for brain disorders [5].
2. Materials and Methods
Clinical and gene expression data from 19 subjects (Table 1)
meetingDSM-IVcriteriaforatleastoneepisodeofpsychosis
were acquired from a larger gene expression study of blood-
based biomarkers of schizophrenia and bipolar disorder
(GEO Accession number: GSE18312). All subjects were
currently taking psychotropic medication and were excluded
if any of the following were present: (1) substance abuse or
dependence in the past year, (2) neurologic problems (e.g.,
stroke, meningitis), (3) systemic medical illnesses (e.g., heart
disease,diabetes),(4)historyofheadinjurywithdocumented
loss of consciousness lasting longer than 10 minutes, (5)
pregnancy, or (6) physical disabilities. More details on the2 Psychiatry Journal
T 1: Sample characteristics.
Variable Total (𝑛𝑛 𝑛 𝑛𝑛)
Age: mean years (sd) 43 (9)
Sex: female 𝑛𝑛 (%) 6 (32)
Education: mean years (sd) 13 (2)
Ancestry: 𝑛𝑛 (%)
European 10 (53)
African 6 (32)
Hispanic 2 (10)
Asian 1 (5)
Current smoker: 𝑛𝑛 (% yes) 13 (68)
Past 6-month substance use: 𝑛𝑛 (% yes) 3 (16)
Current medication use: 𝑛𝑛 (% yes)
Antipsychotic 16 (84)
Mood stabilizer 7 (37)
History of psychosis: 𝑛𝑛 (% yes) 19 (100)
Positive symptoms: mean score (sd)
1
Hallucinations 2.8 (1.7)
Delusions 2.7 (1.3)
Bizarre behaviors 0.3 (0.5)
Formal thought disorder 0.5 (0.8)
Positive symptom total (SAPS) 1.6 (0.6)
Negative symptoms: mean score (sd)
1
Aﬀective �attening 1.9 (1.4)
Alogia 1.2 (1.5)
Apathy 2.2 (1.5)
Anhedonia 2.0 (1.7)
Attention 0.3 (0.6)
Negative symptom total (SANS) 1.5 (0.8)
𝑛Higher scores re�ect greater severity (range 0–5).
SAPS: Scale for the Assessment of Positive Symptoms.
SANS: Scale for the Assessment of Negative Symptoms.
recruitment, inclusion, and exclusion criteria as well as pro-
ceduresusedtodiagnosepsychosisweredescribedpreviously
[6].Wholebloodsamples(10mL)werecollectedintoEDTA-
coated collection tubes the morning aer subjects fasted
overnight. Preparation of blood samples, separation, and
lysis of PBMCs, extraction, puri�cation, and hybridization
of RNA, quanti�cation of expression levels on GeneChip
Human Exon 1.0ST Arrays (Aﬀymetrix, Inc.; Santa Clara,
CA), and quality-control procedures were all performed by
standard methods, which are described in greater detail
elsewhere [6, 7]. All study procedures were approved by the
Institutional Review Board at University of California, San
Diego.
2.1. Negative and Positive Symptom Severity Measurement.
eScalesfortheAssessmentofPositiveandNegativeSymp-
toms (SAPS-SANS) [8] were administered to all subjects by a
trainedMaster’s-levelresearchassistantandlaterreviewedby
two independent doctoral-level clinicians to ensure accurate
scoring. e SAPS assesses four distinct positive symptom
subcategories (i.e., hallucinations, delusions, bizarre behav-
ior, and thought disorder), whereas the SANS assesses �ve
negative symptom subcategories (i.e., aﬀective �attening,
alogia, avolition, anhedonia-asociality, and attention) on a
severity scale of zero (none) to �ve (severe). For the current
study, the four and �ve subcategory scores were averaged
to create global scores for positive and negative symptoms,
respectively (Table 1).
2.2. Gene Selection. e number of genes that popu-
late the Wnt/beta-catenin signaling pathway is continually
changing, and a consensus on the number has not been
achieved. We focused on 25 of the most well-characterized
genes involved in the Wnt signaling pathway, based on
the Kyoto Encyclopedia of Genes and Genomes database
(http://www.genome.jp/kegg/). ese genes included v-akt
murine thymoma viral oncogene homolog (AKT1), ade-
nomatous polyposis coli (APC), axin 1 (AXIN1), catenin
beta 1 (CTNNB1), disrupted in schizophrenia 1 (DISC1),
Dickkopf homologs 1, 3, and 4 (DKK1, 3, 4), disheveled
homologs 1–3 (DSL1–3), frizzled homologs 1–8 (FZD1–8),
glycogensynthasekinase3alpha(GSK3A)andbeta(GSK3B),
low density lipoprotein receptor-related proteins 5 (LRP5)
and 6 (LRP6), transcription factor 4 (TCF4), and wingless-
type MMTV integration site family member 1 (WNT1).
Although many genes that were not included may provide
further insight into the Wnt signaling pathway as it relates to
psychotic symptoms, we were careful to select both up- and
downstream genes within the pathway in an eﬀort to provide
an adequate proxy of Wnt pathway functioning.
2.3. Statistical Analysis. Data preparation and analysis pro-
cedures have been described in detail elsewhere [3]. Brie�y,
Spearman’s correlations were conducted between expression
intensities for each of the 25 selected Wnt pathway genes
and SANS-SAPS global severity scores, adjusting for gender,
ethnicity, age, education, current smoking (yes/no), and past
six-month substance use (yes/no). Due to the in�ated proba-
bility of committing type-I errors in this study a Bonferroni-
adjusted alpha threshold of 0.05/50 𝑛 0.00𝑛 was used.
3. Results
Two (DVL2 and GSK3B) of the 25 WNT signaling pathway
genes examined were nominally correlated with scores on
the SANS however, only DVL2 remained signi�cant aer
Bonferroni correction. DVL2 showed a negative correlation
whereas, GSK3B was positively correlated with the SANS
(Figure 1). Additionally, TCF4 showed a trend toward neg-
ative correlation (𝑟𝑟 𝑛 𝑟0.43, 𝑃𝑃 𝑛 0.0𝑃0) with negative
symptoms. Post hoc exploration of the four subscales of
the SANS revealed signi�cant negative correlations between
DVL2 expression and aﬀective �attening (𝑟𝑟 𝑛 𝑟0.55, 𝑃𝑃𝑛
0.0𝑛5) and alogia (𝑟𝑟 𝑛 𝑟0.𝑃5, 𝑃𝑃 𝑛 0.00𝑃) severity. GSK3B
expression was positively correlated with alogia (𝑟𝑟 𝑛 0.𝑃0,
𝑃𝑃 𝑛 0.00𝑃) only. None of the 25 gene transcripts examined
signi�cantly correlated with severity scores on the SAPS. We
were unable to perform qRTPCR validation for our genes
of interest due to inadequate mRNA quantities althoughPsychiatry Journal 3
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F 1: Correlations between severity of negative symptoms (SANS) and expression of two Wnt Pathway genes, dishevelled 1 (DVL1) and
glycogen synthase kinase 3 beta (GSK3B). Higher scores on the SANS re�ect greater severity.
previous work with the current sample has successfully
validated genes using qRTPCR [6].
4. Discussion
Our results show that lower expression of DVL2 a n dt oa
lesser extent higher expression of GSK3B are associated with
moreseverenegativebutnotpositivesymptomsinpsychosis.
To our knowledge, no study has examined the association
between psychosis symptom severity and gene expression in
the Wnt signaling pathway. Furthermore, we are unaware of
anystudylinkingDVL2geneexpressiontopsychosisorother
major psychiatric disorders, although numerous studies have
implicated GSK3B in the pathogenesis of schizophrenia as
well as antipsychotic drug action [1].
As the current study was designed to identify poten-
tial biomarkers in peripheral blood for psychosis symptom
severity, we do not assume that our �ndings represent
the underlying biological mechanisms by which clinically
observed symptom severity emerges. However, our results
are aligned with those of Emamian and associates [9] who
reported decreased phosphorylation of GSK3B at Ser9 in
peripherallymphocytesandfrontalcortexofindividualswith
schizophrenia, suggesting increased GSK3B activity. Our
results are further supported by numerous in vitro studies
demonstrating that disheveled homologues, such as DVL2,
inhibit GSK3B phosphorylation of beta-catenin [10, 11] as
well as work carried out within our laboratory demonstrat-
ing reduced levels of beta-catenin in the hippocampus of
schizophrenicsubjects[12],indicativeofincreasedactivityof
GSK3B.However,contrary�ndingshavebeenreportedbyus
and others showing no diﬀerence in GSK3B mRNA levels in
lymphocytes [13] and protein levels in the prefrontal cortex
[14] compared to controls.
Several lines of investigation have reported links between
genes associated with the Wnt signaling pathway and
schizophrenia [2, 15], most of which were included in the
current analysis. Only two of the 25 genes examined were
nominally associated with psychosis symptom severity. Our
ability to uncover signi�cant gene correlates involved in the
Wnt signaling pathway may have been inhibited by several
limitations within our study. First, the sample was small
and may have prohibited us from detecting correlations
that would have attained statistical signi�cance in a larger
sample. In fact, TCF4, one of only three genes correlated
with schizophrenia at the whole genome level [16], had
a large expression eﬀect (𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟𝑟; data not shown)
[17] for negative symptoms suggesting that a signi�cant
correlation may have been observed in a larger sample.
Second, we included subjects with schizophrenia or bipolar
disorder with a history of psychosis. is decision was
made on the assumption that psychosis symptoms in both
disorders are similar and that an increase in the sample
size and subsequent power would outweigh any potential
statistical noise introduced by combining the two disorders.
ird, all of the 19 participating subjects were taking psy-
chotropic medication, which could have arti�cially reduced
or in�ated our observed correlations with symptom severity.
Data from the Stanley Medical Research Institute Online
Genomics Database (http://www.stanleygenomics.org/) sug-
gest that DVL2 is upregulated in postmortem brains of
patients with greater than 5000mg of lifetime antipsychotic
exposure. In addition, lithium [18]a sw e l la sc l o z a p i n e ,o l a n -
zapine,risperidone,quetapine,andziprasidoneareknownto
inhibit GSK3Binthemouseandratbrain[19,20]. More than
half (53%, 𝑛𝑛𝑟𝑛 𝑟 ) of the 19 subjects in the current study
were taking one or more of these medications at the time
of assessment but post hoc adjustment for presence of one
of these medications showed no diﬀerence in our reported
results. erefore, these results serve as preliminary evidence
that the Wnt signaling pathway may harbor biomarkers for
(primarilynegative)symptomseverityinpsychoticdisorders.
Futurelongitudinalstudiesdesignedaprioritoexaminegene
expression prior to, during, and aer a psychotic episode
andinitiationofpharmacologicaltreatmentwouldclarifythe
biomarker potential of this pathway for psychosis symptom
severity. Finally, it remains unclear whether expression in
peripheral blood accurately re�ects that found in the brain
[21]. However, it is not a requirement for a biomarker to
be linked etiologically to the phenotype of interests. Future4 Psychiatry Journal
postmortem expression studies with access to antemortem
clinicaldatacouldfurtherstrengthenourresults.Inaddition,
future research examining expression of a larger pool of
Wnt signaling genes including DVL2 and GSK3B using more
sensitive techniques (e.g., qRTPCR) is also warranted. If
replicated, these results provide potential �rst steps toward
development of objective tools for characterizing psychosis
symptom pro�les in clinical practice.
5. Conclusion
Our results support previous work and provide preliminary
data suggesting the Wnt signaling pathway as one of poten-
tially many pathways harboring transcriptomic biomarkers
for negative symptom severity in psychosis.
Con�ic�of �n�eres�s
�e authors do not have any con�ict of interests with the
content of the paper.
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